DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for pilocytic astrocytoma — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePilocytic astrocytoma maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pilocytic astrocytoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A) — PRKAR1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pcgdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5KJZ · 1.347 Å · ligand CYCLIC GUANOSINE MONOPHOSPHATE (PCG). Experimental structure, not a prediction.
What the evidence adds up to
In a 2016 study of five pilocytic astrocytoma specimens, the blood-brain barrier was not completely broken down. Moderately enhancing regions showed intact vasculature surrounded by dense GFAP staining but reduced and disorganised aquaporin 4 staining, indicating that tumour cells could not provide the physiological support that a normal blood-brain barrier requires. The authors concluded that pharmaceutical agents designed to exploit a disrupted blood-brain barrier might be warranted in pilocytic astrocytoma, but they did not test any such agent.
A 1998 cytodiagnostic review of 23 pilocytic astrocytomas confirmed that the tumours are moderately cellular with a myxoid background, contain bipolar hair-like cells, Rosenthal fibres, eosinophilic granular bodies, and hyalinised vessels. Mitoses and necrosis were absent. The study was purely diagnostic and offered no treatment data.
A 2014 review of genetic and molecular factors stated that the exact mechanism of pilocytic astrocytoma pathogenesis remains undetermined and that concordance between studies is difficult to obtain. The most important causative factors appear to be NF1 gene inactivation in neurofibromatosis type 1 cases and BRAF gene overexpression in sporadic cases, both leading to MAPK/Erk pathway upregulation. Other alterations, such as mTOR or PI3K pathway deregulation and Matrilin 2 overexpression, may be associated with more aggressive or recurrent tumours. The review did not report any clinical trial results or survival outcomes.
What is still missing is a clinical trial that tests a drug specifically in pilocytic astrocytoma patients, with sufficient sample size to detect a survival or response benefit. The blood-brain barrier data come from only five cases, and the genetic review notes that no unified mechanism has been established. Patient stratification by NF1 status, BRAF alteration, or blood-brain barrier integrity has not been prospectively tested. Funding for a dedicated paediatric trial remains the primary gap.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Interdisciplinary Histopathology · 2016 · 33 citations · open access
Characterization of the Blood Brain Barrier in Pediatric Central Nervous System Neoplasms
AbstractOBJECTIVE: The normal blood-brain barrier (BBB) is composed of tight junctions between endothelial cells and surrounding astrocyte foot processes. Breakdown of the physiological astrocyte-endothelial cell relationship occurs in adult metastatic and primary brain tumors. However, the astrocyte-endothelial cell relationship has not been studied in pediatric tumors. MATERIALS AND METHODS: Utilizing specimens from cases of pilocytic astrocytoma (n = 5), medulloblastoma (n = 5), and low-grade diffuse astrocytoma (n = 1), immunofluorescence were performed using primary antibodies against CD31, glial fibrillary acidic protein (GFAP), and aquaporin 4 (AQ4). Clinical, magnetic resonance imaging, operative, and histopathological findings were analyzed. RESULTS: Strongly-enhancing areas of medulloblastoma exhibited complete BBB breakdown with sparse GFAP and AQ4 staining around CD31-positive vessels. Moderately enhancing regions of pilocytic astrocytomas exhibited regions of intact BBB and vasculature surrounded by dense GFAP staining but reduced and disorganized AQ4 staining, suggesting tumor cells could not fulfill physiological BBB support. Non-enhancing low-grade diffuse astrocytoma demonstrated intact BBB with intense peri-microvasculature GFAP and AQ4 staining. AQ4 stained so strongly that AQ4 visualization alone delineated CD31-positive vessels. CONCLUSION: Taken together, BBB breakdown in pediatric tumors corresponds to a loss of normal endothelial cell-astrocyte foot process relationships. Further development of pharmaceutical agents capitalizing on this disrupted BBB is warranted in medulloblastoma and pilocytic astrocytoma. However, BBB integrity remains a challenge in treating low-grade diffuse astrocytoma before progression toward secondary glioblastoma.
Cytodiagnosis of Pilocytic Astrocytoma in Smear Preparations
AbstractOBJECTIVE: To assess the cytologic features in smear preparations of 23 pilocytic astrocytomas. STUDY DESIGN: Examination of 23 smears. RESULTS: In all cases, the diagnosis was subsequently confirmed on histologic sections. The smears were moderately cellular, with a variably myxoid background. They showed bipolar "hair" cells with elongated, coarse cytoplasmic processes; bland, oval nuclei; Rosenthal fibers; eosinophilic granular bodies; and hyalinized vessels. Stellate cells and bare tumor nuclei were also present. Nuclear pleomorphism, vascular proliferation, perivascular pseudorosettes, microcalcification and hemosiderin-laden macrophages were infrequent features. Mitoses and necrosis were absent. The differential diagnosis should include diffuse fibrillary astrocytomas of all histologic grades, pleomorphic xanthoastrocytoma, ganglion cell tumor, ependymoma and reactive gliosis. CONCLUSION: Correlation of cytologic features with clinical and radiologic information allows pilocytic astrocytoma to be distinguished from other conditions.
Pilocytic astrocytoma: a review of genetic and molecular factors, diagnostic and prognostic markers.
AbstractIn spite of numerous studies concerning the pathogenesis of pilocytic astrocytoma (PA), the exact mechanism of the process still remains undetermined. It is difficult to obtain concordance between particular studies, which makes review of existing data especially troublesome. Nevertheless, the most important causative factors seem to be NF1 gene inactivation, in cases related to neurofibromatosis type 1, and BRAF gene overexpression in sporadic PAs, both resulting in MAPK/Erk pathway upregulation. Other molecular alterations, like mTOR or PI3K pathway deregulation, or Matrilin 2 overexpression, may influence the course of the disease, leading to the development of more aggressive and recurrent tumors. In the current paper we review genetic alterations in PA and describe currently studied molecular markers that may contribute to the development of the tumor and can be used in pathological staging of the malformation.
AbstractThis represents the largest study of single-session GKRS for pilocytic astrocytoma to date. Favorable long-term PFS and overall survival were observed with GKRS. Further prospective studies should be performed to evaluate appropriate radiosurgery dosing, timing, and sequencing of treatment along with their impact on toxicity and the quality of life of patients with pilocytic astrocytoma.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
